Prescription medicine
Thallous chloride tl 201
Thallous chloride tl 201 is a prescription medicine with an FDA approval on record since 1977. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the thallous chloride tl 201 FDA label on DailyMed (effective December 22, 2025, Curium US LLC); the NDA 17806 record on Drugs@FDA; every thallous chloride tl 201 label on DailyMed.
Highlights of the record
FDA label of December 22, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageThallous Chloride Tl 201 Injection is indicated for use with planar scintigraphy or single-photon emission computed tomography (SPECT) for the following applications: Myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stres
Forms and strengths
Injection (solution).
On the market
- Earliest approval on file
- December 16, 1977 Thallous Chloride Tl 201, Lantheus Medcl; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 2 first November 21, 2001; 0 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 0 since 2012 0 Class I among all firms' recalls; 1 more by firms not listed as its makers
- FAERS reports
- 51 through July 30, 2026
What is thallous chloride tl 201 used for?
From the label: indications and usageThallous Chloride Tl 201 Injection is indicated for use with planar scintigraphy or single-photon emission computed tomography (SPECT) for the following applications: Myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress Localization of sites of parathyroid hyperactivity pre- and post-operatively in adults with elevated serum calcium and parathyroid hormone levels Thallous Chloride Tl 201 Injection is a radioactive diagnostic drug indicated for use with planar scintigraphy or single-photon […]
FDA pharmacologic class: Radioactive Diagnostic Agent.
Source: FDA drug label (THALLOUS CHLORIDE Tl 201), Curium US LLC, effective December 22, 2025 (SPL set 0da81fc0-a137-46d3-9378-d8053a82e61a), via openFDA; the full label on DailyMed
Is there a generic for thallous chloride tl 201?
The FDA approved the first generic thallous chloride tl 201 on November 21, 2001. 2 generic applications are approved; 0 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
- 1977 earliest approval on file
- 2001 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Has thallous chloride tl 201 been recalled?
The FDA's Enforcement Report lists 1 recall naming thallous chloride tl 201 since 2012: 0 Class I (the most serious), 0 Class II, 1 Class III; 0 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of thallous chloride tl 201 and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| July 30, 2012 | Class III | Mallinckrodt Inc not a listed maker | Labeling: Correct Labeled Product Miscart/Mispack: labels on outer containers do not match labels on vials (the correct label) |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What do FAERS reports show for thallous chloride tl 201?
The FDA Adverse Event Reporting System holds 51 reports that list thallous chloride tl 201 among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 7 are coded as a death and 8 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other radioactive diagnostic agents
- the pharmacologic class, with prices and generics
- Thallous chloride tl 201 side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other